Lantern Pharma(LTRN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184, enabling advancement to upc ...